Reports Q1 revenue $38.9M, consensus $34.38M. Cash, cash equivalents, and investments, excluding short- and long-term restricted cash, at March 31 totaled $874.9M, compared to $772.3M at December 31, 2022. "PacBio is off to a strong start this year with record quarterly revenue. The Revio launch is exceeding our expectations with our customers achieving performance above our specifications for the system," said Christian Henry, President and CEO. "We’ve shipped to dozens of customers worldwide who’ve shared their excitement for deploying Revio’s paradigm-changing throughput and economics. Strong customer demand continued in the first quarter and we ended Q1 with our second consecutive quarter of record backlog."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio Announces Record Revenue in First Quarter 2023
- PACB Upcoming Earnings Report: What to Expect?
- Pacific Biosciences upgraded to Outperform from Market Perform at TD Cowen
- Pacific Biosciences announces new workflows developed with Corteva
- Pacific Biosciences begins commercial shipment of Revio sequencing systems